While clinical deprescribing trials are increasingly being performed, there is no guidance on the optimum conduction of such studies. The aim of this survey was to explore the perspectives, attitudes, interests, barriers, and enablers of conducting clinical deprescribing trials among health professionals and researchers. An anony- 
| INTRODUC TI ON
Deprescribing has been identified as the patient-centered process of withdrawing potentially harmful or unnecessary medications in order to improve health outcomes. 1 Despite many deprescribing studies being in progress internationally, there is an ongoing recognition of the need to conduct quality, robust clinical deprescribing trials to investigate the benefits and safety of stopping medicines. [2] [3] [4] However, study design and outcomes often vary, leading to great heterogeneity in the literature, and presenting challenges for researchers and practitioners to synthesize results and implement recommendations into clinical practice. [5] [6] [7] [8] The primary challenge in deprescribing research is the weighing of risks the patient may accept against the potential benefits of discontinuing a drug. 9 The recognition of more information on appropriate medication use has been highlighted by the World Health
Organization, who have established Medication Without Harm as the theme of the third Global Patient Safety Challenge, with an overall goal of reducing severe avoidable medication-harm by 50% globally. 10 To improve the knowledge on the safety of deprescribing, researchers and health professionals have called for more high-quality evidence, requiring more clinical deprescribing trials. [11] [12] [13] Definitive clinical deprescribing trials would not only inform on the safety of deprescribing but also provide guidance on assessment of relevant outcomes.
While there are international clinical deprescribing guidelines, there is no Consolidated Standards of Reporting Trials (CONSORT) extension nor recognized framework for conducting clinical deprescribing trials. 11, [13] [14] [15] [16] [17] Furthermore, while numerous studies have examined the perspectives on deprescribing from health professionals and patient groups, only one has explored the perspectives of those individuals who conduct the deprescribing trials. 5, 12, [18] [19] [20] [21] [22] [23] [24] [25] [26] However, this study only gathered the opinions of a selected group of researchers and health professionals in a research workshop setting, and did not systematically analyze the ideas brought forward to evaluate their recommendations. 12, 24 Instead a World Café, open dialogue session with roundtable discussion, was used with three questions on: research priorities for developing; outcome measures to inform; and, how to evaluate the implementation of, deprescribing guidelines in clinical settings. 12, 24 Nor did this study examine other themes specific to clinical trials such as participant recruitment, ethical approval barriers, or the most appropriate study design.
Given that increasing numbers of deprescribing trials are currently being conducted, direction is needed on their design, conduct, and reporting. 27 Yet, at present, there is little data on health professionals' and researchers' perspectives and experiences about conducting deprescribing clinical trials.
| AIM
To determine the perspectives, attitudes, interests, and perceived barriers and enablers in relation to conducting clinical deprescribing trials among health professionals and researchers.
| MATERIAL S AND ME THODS
This cross-sectional survey is reported per the Checklist for
Reporting Results of Internet E-Surveys (CHERRIES). 28 Ethics approval for this study was granted by The University of Sydney's Human Research Ethics Committee, Sydney, Australia.
| Design
An anonymous, online survey was created using Research Data Electronic Capture (REDCap) software hosted on University of Sydney servers, and consisted of a nonrandomized mix of multiple-
choice questions and open-ended options.
Twelve questions were developed, reviewed and piloted by all investigators for content validity. In addition, we sought input on questionnaire content from key national (n = 2) and international (n = 2) experts with experience in conducting deprescribing trials. The questions were formulated based on current clinical trial frameworks and addressed themes identified as barriers and enablers in current literature. 15 The final questionnaire consisted of 10 multiple-choice
questions (with open-ended options) exploring participants' experi- 
| Participants

| Analysis of results
| RE SULTS
Cookie data collected by REDCap indicated there were 117 unique site visitors with 104 respondents completing the baseline data (88.9% participation rate), and 96 completing at least one survey question (92.3% completion rate). Of these, 84 respondents submitted the completed survey with all questions answered ( Figure 1 ).
The mean age of respondents was 45.0 (SD ± 11.6), and majority was female (54.3%) ( Table 1) . Canada was the most popular base for respondents (31.7%), and most respondents were academics (34.7%). Less than half (41.3%) of respondents indicated that they had previous experience in conducting clinical deprescribing trials.
There were no significant differences between responses to all questions based on participants' previous experience in conducting clinical deprescribing trials.
| Rationale, barriers, and enablers of conducting clinical deprescribing trials
In relation to survey sample size, 96 respondents completed at least one question and respondents could submit more than one response or skip questions giving different sample sizes for each question.
The first three questions explored the rationale, and common barriers and enablers of conducting clinical deprescribing trials (Table 2 ). Respondents overwhelmingly indicated that the primary rationale for deprescribing studies is to "optimise clinical and/or patient centered outcomes" (79.2 ± 8.1%). Common enablers to conducting trials were "the beliefs of other health professionals regarding benefits of deprescribing" (24.4%), and "willingness of patients to participate" (20.9%). Common barriers to completing trials were the "time and effort required" (18.2%), and "establishing and/ or maintaining relationships with other health professionals" (17.1%).
| Pretrial approval and participant recruitment barriers
In seeking ethical approval for deprescribing trials ( Note: Participants were able to select more than one option for barriers and enablers; N = 96.
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professionals… influencing the decision" (31.0%) and "recruitment of participants who are unable to consent" (27.7%).
| Appropriateness of clinical trial methodologies and participant recruitment sites
In determining appropriate study methodologies and sites ( Figure 2) respondents indicated most classical trial designs were suitable (79.7%-93.2%). Classical parallel RCTs were considered the most appropriate (93.2 ± 6.0%) vs "crossover" studies (45.2 ± 12.4%).
Respondents indicated this was because it would not be safe to restart potentially harmful drugs. All options for study recruitment sites (hospital in and out-patients, nursing homes, and community settings) were deemed appropriate (81.3%-98.8%), although hospital in-patient sites were considered the least appropriate (81.3 ± 9.8%) due to a heterogeneous patient group and time constraints.
| Potential need for future framework and CONSORT list amendment
Finally, respondents were asked if they believed a "legal, regulatory and good clinical practice framework" needed to be developed for clinical deprescribing trials, and whether the CONSORT list required amending to include deprescribing trials ( Figure 3 ). Most respondents indicated that a good clinical practice framework did need to be developed (60.0 ± 11.0%), but that the current CONSORT list did not need amending (38.9% yes ± 11.6%). There was greater resistance to amending the CONSORT list if participants had previously conducted clinical deprescribing trials compared to those who had not been involved in clinical deprescribing trials (70.3% vs 51.4%, respectively), although this was not significant (Table 4 ). There was little difference in support levels for a clinical deprescribing framework based on previous clinical deprescribing trial experience (59.0% experienced vs 61.0% no experience) ( Table 4) . Note: Participants could select more than one option; N = 96.
| D ISCUSS I ON
To our knowledge, this is the first study that has systematically investigated the perspectives, attitudes, interests, barriers, and enablers in relation to conducting clinical deprescribing trials among health professionals and researchers internationally.
Respondents cited the main rationale for conducting deprescribing studies is to optimize patient-centered outcomes, and indicated that the positive beliefs of participants and their treating clinicians regarding deprescribing were the greatest enablers. The most common barriers were the time and effort required for a clinical deprescribing trial, and the apprehension toward deprescribing of a health professional involved in the study, especially if they are involved in participant recruitment. Finally, respondents specified that classical RCTs are the most appropriate trial methodology to employ and should form the backbone of any good clinical practice framework.
The attitudes, interests, barriers, and enablers of conducting clinical deprescribing trials did not alter whether respondents had previously conducted studies or not.
The primary concern reported by health professionals regarding deprescribing is safety. 5, 12, 18, [20] [21] [22] 25 Ensuring patient safety should be the primary factor in influencing any decision made by a treating clinician-but often there is uncertainty on what deprescribing involves and its potential benefits; especially in vulnerable patient groups. 12 These vulnerable patient groups, including those "where consent must be acquired through a proxy", and those who "transition through various healthcare settings", were recognized as the most difficult patients to enroll and retain in clinical deprescribing trials (39.5% and 44.2%, respectively). This challenge extends to when institutional ethical approval is sought, with the most commonly identified barrier being the recruitment of "vulnerable participants", and those "unable to provide… consent" (18.9% and 18.5%, respectively).
Previous studies, however, have demonstrated that patients, while having strong preexisting attitudes toward drug use, are willing to cease treatments if there may be a positive health benefit, they can reduce their drug burden, and it is deemed appropriate by their doctor. 19, 23, 26 This is reflected with the strong response on caregiver. 26 To utilize these beliefs, and ensure adequate participant recruitment, patients, and care givers, must be presented with evidence on the potential benefits of deprescribing, and how patient safety will be ensured.
To overcome prescribers' and participants' fears, a rigorous trial methodology must be practiced and respondents strongly indicated that parallel RCTs (93.2%) and cluster RCTs (92.9%) were the most appropriate trial methods for clinical deprescribing trials. Implementation/pre-post studies were also deemed by most respondents as appropriate (79.7%), although crossover trials were deemed as not appropriate (54.8%). These attitudes toward crossover trials are reflected in current literature; with a recent narrative review finding that of 33 randomized controlled trials deprescribing single drugs, 32 employed a parallel design. 30 Also, this review supported the assertions of this survey's respondents, in deeming that community and residential aged care settings (98.8% each) are the most suitable recruitment sites, with only four studies recruiting from other sites.
Despite the popularity of using RCTs in deprescribing research, some studies have incorporated a crossover methodology for deprescribing, with a systematic review identifying six such trials. 31 These studies generated "strong patient-specific evidence" on the effec- Considering the safety concerns of health professionals treating patients, the willingness of patients to participate, and the reported lack of strong evidence, it is surprising that 40% of respondents indicated that a "good clinical practice framework for clinical deprescribing trials" was not required. Also, 61.1% of respondents indicated that the current CONSORT list did not need to be amended. Respondents thought that any framework or CONSORT list modification would increase the amount of red tape that already surrounds deprescribing trials. Also, respondents felt that there are already sufficient good clinical practice frameworks and that deprescribing trials can be conducted under current CONSORT extensions. However, of those who did indicate the need for a "good clinical practice framework", the 
| Strengths and limitations
The main strength was that this survey was informed by interna- 
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